Binding Site Information of Target
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T40332 | Target Info | |||
| Target Name | Neutrophil elastase (NE) | ||||
| Synonyms | PMN elastase; Medullasin; Human leukocyte elastase; HLE; Elastase-2; ELA2; Bone marrow serine protease | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | ELANE | ||||
| Biochemical Class | Peptidase | ||||
| UniProt ID | |||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: MDL 101,146 | Ligand Info | |||||
| Structure Description | CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE WITH MDL 101, 146 | PDB:1B0F | ||||
| Method | X-ray diffraction | Resolution | 3.00 Å | Mutation | No | [1] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 AGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA64 VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFEDGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRNRGIASVL155 QELNVTVVTS166 LCRRSNVCTL 184 VRGRQAGVCF192 GDSGSPLVCN204 GLIHGIASFV216 RGGCASGLYP225 DAFAPVAQFV 235 NWIDSIIQ
|
|||||
|
|
||||||
| Ligand Name: 1-(3-Chlorophenyl)-5-(3,5-Dimethylisoxazol-4-Yl)-6-Methyl-N-[4-(Methylsulfonyl)benzyl]-2-Oxo-1,2-Dihydropyridine-3-Carboxamide | Ligand Info | |||||
| Structure Description | Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases | PDB:5ABW | ||||
| Method | X-ray diffraction | Resolution | 1.60 Å | Mutation | No | [2] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GGIASVLQEL158 NVTVVTSLCR177 RSNVCTLVRG 186A RQAGVCFGDS195 GSPLVCNGLI209 HGIASFVRGG219 CASGLYPDAF228 APVAQFVNWI 238 DSIIQ
|
|||||
|
|
||||||
| Ligand Name: 5-[(6r)-5-Ethanoyl-4-Methyl-2-Oxidanylidene-3-[3-(Trifluoromethyl)phenyl]-1,6-Dihydropyrimidin-6-Yl]pyridine-2-Carbonitrile | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A0A | ||||
| Method | X-ray diffraction | Resolution | 1.78 Å | Mutation | No | [3] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRGIASVLQE157 LNVTVVTSLC168 RRSNVCTLVR 186 GRQAGVCFGD194 SGSPLVCNGL208 IHGIASFVRG218 GCASGLYPDA227 FAPVAQFVNW 237 IDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .JJS or .JJS2 or .JJS3 or :3JJS;style chemicals stick;color identity;select .E:57 or .E:94 or .E:95 or .E:96 or .E:99 or .E:100 or .E:102 or .E:190 or .E:191 or .E:192 or .E:194 or .E:195 or .E:196 or .E:213 or .E:214 or .E:215 or .E:216 or .E:220 or .E:227; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 2-[(4r)-4-(4-Cyanophenyl)-5-Ethanoyl-6-Methyl-2-Oxidanylidene-1-[3-(Trifluoromethyl)phenyl]-4h-Pyrimidin-3-Yl]ethanoic Acid | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A09 | ||||
| Method | X-ray diffraction | Resolution | 1.81 Å | Mutation | No | [3] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRNRGIASVL155 QELNVTVVTS165 LCRRSNVCTL 184 VRGRQAGVCF192 GDSGSPLVCN202 GLIHGIASFV216 RGGCASGLYP225 DAFAPVAQFV 235 NWIDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .JJD or .JJD2 or .JJD3 or :3JJD;style chemicals stick;color identity;select .A:57 or .A:94 or .A:95 or .A:96 or .A:99 or .A:100 or .A:102 or .A:190 or .A:191 or .A:192 or .A:194 or .A:195 or .A:196 or .A:213 or .A:214 or .A:215 or .A:216 or .A:220 or .A:227; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: Methyl {(7R)-6-cyano-7-(4-cyanophenyl)-5-methyl-4-[3-(trifluoromethyl)phenyl]-4,7-dihydro[1,2,4]triazolo[1,5-A]pyrimidin-2-YL}carbamate | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A8Y | ||||
| Method | X-ray diffraction | Resolution | 1.90 Å | Mutation | No | [4] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRGIASVLQE157 LNVTVVTSLC168 RRSNVCTLVR 186 GRQAGVCFGD194 SGSPLVCNGL208 IHGIASFVRG218 GCASGLYPDA227 FAPVAQFVNW 237 IDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .VBM or .VBM2 or .VBM3 or :3VBM;style chemicals stick;color identity;select .A:57 or .A:94 or .A:95 or .A:96 or .A:99 or .A:100 or .A:102 or .A:190 or .A:191 or .A:192 or .A:194 or .A:195 or .A:196 or .A:213 or .A:214 or .A:215 or .A:216 or .A:217 or .A:220 or .A:227; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: (2S)-3-methyl-2-[(2S,3R)-3-[(methylsulfonyl)amino]-1-{[2-(pyrrolidin-1-ylmethyl)-1,3-oxazol-4-yl]carbonyl}pyrrolidin-2-yl]butanoic acid | Ligand Info | |||||
| Structure Description | Crystal structure of human neutrophil elastase complexed with an inhibitor (GW475151) | PDB:1H1B | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [5] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA64 VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRNRGIASVL155 QELNVTVVTS166 LCRRSNVCTL 184 VRGRQAGVCF192 GDSGSPLVCN204 GLIHGIASFV216 RGGCASGLYP225 DAFAPVAQFV 235 NWIDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .151 or .1512 or .1513 or :3151;style chemicals stick;color identity;select .A:57 or .A:99B or .A:99A or .A:99 or .A:177 or .A:190 or .A:191 or .A:192 or .A:193 or .A:194 or .A:195 or .A:213 or .A:214 or .A:215 or .A:216 or .A:217A or .A:220; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 2-Hydroxyethyl (4r)-4-(4-Cyanophenyl)-6-Methyl-2-Oxo-1-[3-(Trifluoromethyl)phenyl]-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate | Ligand Info | |||||
| Structure Description | Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:3Q77 | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [6] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA64 VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRNRGIASVL155 QELNVTVVTS166 LCRRSNVCTL 184 VRGRQAGVCF192 GDSGSPLVCN204 GLIHGIASFV216 RGGCASGLYP225 DAFAPVAQFV 235 NWIDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .2HY or .2HY2 or .2HY3 or :32HY;style chemicals stick;color identity;select .A:57 or .A:61 or .A:94 or .A:95 or .A:98 or .A:99B or .A:100 or .A:102 or .A:190 or .A:191 or .A:192 or .A:194 or .A:195 or .A:196 or .A:213 or .A:214 or .A:215 or .A:216 or .A:220 or .A:227; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 4-[(4r)-7-Methyl-2,5-Bis(Oxidanylidene)-1-[3-(Trifluoromethyl)phenyl]-3,4,6,8-Tetrahydropyrimido[4,5-D]pyridazin-4-Yl]benzenecarbonitrile | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A8Z | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [4] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GGIASVLQEL158 NVTVVTSLCR177 RSNVCTLVRG 186A RQAGVCFGDS195 GSPLVCNGLI209 HGIASFVRGG219 CASGLYPDAF228 APVAQFVNWI 238 DSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .IUL or .IUL2 or .IUL3 or :3IUL;style chemicals stick;color identity;select .A:57 or .A:94 or .A:95 or .A:96 or .A:99 or .A:100 or .A:102 or .A:190 or .A:191 or .A:192 or .A:194 or .A:195 or .A:196 or .A:213 or .A:214 or .A:215 or .A:216 or .A:220 or .A:227; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: (6s)-6-(4-Cyano-2-Methylsulfonyl-Phenyl)-4-Methyl-2-Oxidanylidene-3-[3-(Trifluoromethyl)phenyl]-1,6-Dihydropyrimidine-5-Carbonitrile | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A0C | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [3] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA66 VRVVLGAHNL 77 SRREPTRQVF87 AVQRIFENGY98 DPVNLLNDIV108 ILQLNGSATI118 NANVQVAQLP 128 AQGRRLGNGV138 QCLAMGWGLL148 GRNRGIASVL159 QELNVTVVTS169 LCRRSNVCTL 188 VRGRQAGVCF199 GDSGSPLVCN209 GLIHGIASFV223 RGGCASGLYP234 DAFAPVAQFV 244 NWIDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .JJV or .JJV2 or .JJV3 or :3JJV;style chemicals stick;color identity;select .A:57 or .A:98 or .A:99 or .A:100 or .A:101 or .A:103 or .A:104 or .A:106 or .A:197 or .A:198 or .A:199 or .A:201 or .A:202 or .A:203 or .A:220 or .A:221 or .A:222 or .A:223 or .A:227 or .A:236; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 3,6,9,12,15,18,21,24,27-Nonaoxanonacosane-1,29-diol | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A0C | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [3] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA66 VRVVLGAHNL 77 SRREPTRQVF87 AVQRIFENGY98 DPVNLLNDIV108 ILQLNGSATI118 NANVQVAQLP 128 AQGRRLGNGV138 QCLAMGWGLL148 GRNRGIASVL159 QELNVTVVTS169 LCRRSNVCTL 188 VRGRQAGVCF199 GDSGSPLVCN209 GLIHGIASFV223 RGGCASGLYP234 DAFAPVAQFV 244 NWIDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .XPE or .XPE2 or .XPE3 or :3XPE;style chemicals stick;color identity;select .A:40 or .A:41 or .A:42 or .A:57 or .A:58 or .A:61 or .A:62 or .A:100 or .A:101 or .A:147 or .A:155 or .A:199 or .A:200 or .A:202; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: (4r)-4-(4-Cyanophenyl)-6-Methyl-2-Oxidanylidene-3-[2-Oxidanylidene-2-(4-Propan-2-Ylpiperazin-1-Yl)ethyl]-1-[3-(Trifluoromethyl)phenyl]-4h-Pyrimidine-5-Carbonitrile | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A0B | ||||
| Method | X-ray diffraction | Resolution | 2.23 Å | Mutation | No | [3] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GGIASVLQEL158 NVTVVTSLCR177 RSNVCTLVRG 186A RQAGVCFGDS195 GSPLVCNGLI209 HGIASFVRGG219 CASGLYPDAF228 APVAQFVNWI 238 DSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .JJX or .JJX2 or .JJX3 or :3JJX;style chemicals stick;color identity;select .A:57 or .A:94 or .A:95 or .A:96 or .A:99 or .A:100 or .A:102 or .A:190 or .A:191 or .A:192 or .A:194 or .A:195 or .A:196 or .A:213 or .A:214 or .A:215 or .A:216 or .A:220 or .A:227; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: ethyl (5R)-5-(4-cyanophenyl)-7-methyl-8-[3-(trifluoromethyl)phenyl]-1,5-dihydroimidazo[1,2-a]pyrimidin-4-ium-6-carboxylate | Ligand Info | |||||
| Structure Description | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | PDB:5A8X | ||||
| Method | X-ray diffraction | Resolution | 2.23 Å | Mutation | No | [4] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GGIASVLQEL158 NVTVVTSLCR177 RSNVCTLVRG 186A RQAGVCFGDS195 GSPLVCNGLI209 HGIASFVRGG219 CASGLYPDAF228 APVAQFVNWI 238 DSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .IUY or .IUY2 or .IUY3 or :3IUY;style chemicals stick;color identity;select .A:57 or .A:94 or .A:95 or .A:96 or .A:99 or .A:100 or .A:102 or .A:190 or .A:191 or .A:192 or .A:194 or .A:195 or .A:196 or .A:213 or .A:214 or .A:215 or .A:216 or .A:220 or .A:227; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 2-(Fluorosulfonyl)benzene-1-sulfonic acid | Ligand Info | |||||
| Structure Description | Ortho-substituted phenyl sulfonyl fluoride and fluorosulfate as potent elastase inhibitory fragments | PDB:6E69 | ||||
| Method | X-ray diffraction | Resolution | 2.33 Å | Mutation | No | [7] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA63C VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRNRGIASVL155 QELNVTVVTS165 LCRRSNVCTL 184 VRGRQAGVCF192 GDSGSPLVCN202 GLIHGIASFV216 RGGCASGLYP225 DAFAPVAQFV 235 NWIDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .HVP or .HVP2 or .HVP3 or :3HVP;style chemicals stick;color identity;select .A:57 or .A:190 or .A:191 or .A:192 or .A:193 or .A:194 or .A:195 or .A:213 or .A:214 or .A:215 or .A:216 or .A:220; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 4-[(2,4-dioxo-1,3-thiazol-1-ium-3-id-5-yl)methyl]-N-[(2S)-4-methyl-1-oxo-1-(2-propylanilino)pentan-2-yl]benzamide | Ligand Info | |||||
| Structure Description | Crystal structure of highly glycosylated human leukocyte elastase in complex with a thiazolidinedione inhibitor | PDB:6F5M | ||||
| Method | X-ray diffraction | Resolution | 2.70 Å | Mutation | No | [8] |
| PDB Sequence |
IVGGRRARPH
25 AWPFMVSLQL35 RGGHFCGATL46 IAPNFVMSAA56 HCVANVNVRA64 VRVVLGAHNL 73 SRREPTRQVF83 AVQRIFENGY94 DPVNLLNDIV104 ILQLNGSATI114 NANVQVAQLP 124 AQGRRLGNGV134 QCLAMGWGLL144 GRNRGIASVL155 QELNVTVVTS166 LCRRSNVCTL 184 VRGRQAGVCF192 GDSGSPLVCN204 GLIHGIASFV216 RGGCASGLYP225 DAFAPVAQFV 235 NWIDSIIQ
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .CQH or .CQH2 or .CQH3 or :3CQH;style chemicals stick;color identity;select .A:35 or .A:36 or .A:59 or .A:60 or .A:61 or .A:62 or .A:62A or .A:62B or .A:64; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Inhibition of human neutrophil elastase. 4. Design, synthesis, X-ray crystallographic analysis, and structure-activity relationships for a series of P2-modified, orally active peptidyl pentafluoroethyl ketones. J Med Chem. 1998 Jul 2;41(14):2461-80. | ||||
| REF 2 | Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores. Bioorg Med Chem Lett. 2015 Oct 15;25(20):4370-81. | ||||
| REF 3 | Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73. | ||||
| REF 4 | Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model. ChemMedChem. 2016 Jan 19;11(2):199-206. | ||||
| REF 5 | Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). J Med Chem. 2002 Aug 29;45(18):3878-90. | ||||
| REF 6 | Unexpected active-site flexibility in the structure of human neutrophil elastase in complex with a new dihydropyrimidone inhibitor. J Mol Biol. 2011 Jun 24;409(5):681-91. | ||||
| REF 7 | SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase. Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):18808-18814. | ||||
| REF 8 | Crystal structure of highly glycosylated human leukocyte elastase in complex with an S2' site binding inhibitor. Acta Crystallogr F Struct Biol Commun. 2018 Aug 1;74(Pt 8):480-489. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.